Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis
Nutrients · 10.02.2023 · 15 (4) · 901
DOI: 10.3390/nu15040901 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Nutrients, online erschienen am 10.02.2023. Verfasst von Jin Hee Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Catechol O-Methyltransferase Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, the National Research Foundation of Korea.
Abstract (Originalsprache)
Levodopa (L-dopa) and catechol-O-methyltransferase (COMT) inhibition are widely used therapeutics in Parkinson’s disease (PD). Despite their therapeutic effects, it was raised that nutrients involved in one-carbon metabolism can be deteriorated by PD therapies. The aim of this meta-analysis was to investigate the impact of L-dopa and COMT inhibitors on levels of homocysteine (Hcy), vitamin B12 and folate in patients with PD. A total of 35 case-control studies from 14 different countries were selected through PubMed, MEDLINE and Google Scholar and were meta-analyzed. In the L-dopa group, the Hcy level was higher compared to the PD without L-dopa group (SMD: 5.11 μmol/L, 95% CI: 3.56 to 6.66). Moreover, vitamin B12 and folate levels in the L-dopa group were lower compared to the healthy control (SMD: −62.67 pg/mL, 95% CI: −86.53 to −38.81; SMD: −0.89 ng/mL, 95% CI: −1.44 to −0.33, respectively). The COMT inhibitor group showed lower levels of Hcy (SMD: −3.78 μmol/L, 95% CI: −5.27 to −2.29) and vitamin B12 (SMD: −51.01 pg/mL, 95% CI: −91.45 to −10.57), but higher folate levels (SMD: 1.78 ng/mL, 95% CI: −0.59 to 4.15) compared to the L-dopa group. COMT inhibitors may ameliorate L-dopa-induced hyper-homocysteine and folate deficiency but exacerbate vitamin B12 deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, Republic of Korea.
- School of Medicine, Ningbo University, Ningbo 315211, China.
- Department of Oriental Pharmaceutical Science and Kyung Hee East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
- Department of Food and Nutrition, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
ORCID-Profile: Hyeyoon Eo, Yunsook Lim
Förderung
- National Research Foundation of Korea
- the National Research Foundation of Korea
Zitieren
APA
Kim, J. H., Jin, S., Eo, H., Oh, M. S., & Lim, Y. (2023). Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis. Nutrients, 15(4), 901. https://doi.org/10.3390/nu15040901
Vancouver
Kim JH, Jin S, Eo H, Oh MS, Lim Y. Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis. Nutrients. 2023;15(4):901. doi:10.3390/nu15040901
BibTeX
@article{Kim2023,
author = {Kim, Jin Hee and Jin, Shaoyue and Eo, Hyeyoon and Oh, Myung Sook and Lim, Yunsook},
title = {Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {4},
pages = {901},
doi = {10.3390/nu15040901}
}
EUVIMED